Roche (ROG) PT Set at CHF 260 by UBS Group
UBS Group set a CHF 260 price objective on Roche (VTX:ROG) in a research report released on Monday morning, www.boersen-zeitung.de reports. The firm currently has a neutral rating on the healthcare company’s stock.
ROG has been the subject of a number of other research reports. Deutsche Bank set a CHF 255 price objective on Roche and gave the company a neutral rating in a research note on Monday, September 11th. Berenberg Bank set a CHF 260 price objective on Roche and gave the company a neutral rating in a research note on Tuesday, October 24th. JPMorgan Chase & Co. reiterated a buy rating on shares of Roche in a research note on Monday, October 9th. Morgan Stanley set a CHF 260 price objective on Roche and gave the company a neutral rating in a research note on Friday, October 6th. Finally, Jefferies Group set a CHF 295 price objective on Roche and gave the company a buy rating in a research note on Monday, October 16th. Three analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company. Roche currently has an average rating of Hold and a consensus target price of CHF 263.42.
Roche (VTX:ROG) opened at CHF 247.20 on Monday. The firm has a market capitalization of $214,660.00 and a PE ratio of 21.97. Roche has a 52 week low of CHF 226.10 and a 52 week high of CHF 273.
ILLEGAL ACTIVITY NOTICE: “Roche (ROG) PT Set at CHF 260 by UBS Group” was first posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/roche-rog-pt-set-at-chf-260-by-ubs-group/1802099.html.
Roche Holding AG (Roche) is a research-based healthcare company. The Company’s operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics.
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.